BioSpace News Archive

Vaxart, Inc. (Nasdaq: VXRT) today announced that it has shown for the first time in clinical trials that its oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier.

Acasti Pharma Inc. announces a reminder that it will host a business update conference call on Wednesday, August 4th at 1:00 PM ET to discuss the planned acquisition of Grace Therapeutics, Inc., a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases, as well as topics related to the annual and special meeting of shareholders.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that the Company will release its second quarter 2021 financial results before the open of the U.S. financial markets on Thursday, August 5, 2021.

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first gynecological (GYN) procedures with the Hugo™ robotic-assisted surgery (RAS) system.

A kidney stone extraction balloon is a surgical device employed to enlarge ureteral structures before the kidney stone removal process, which is done by ureteroscopy.

The Gastric Balloon in healthcare market was valued at US$ 67.3 million in 2018 and it is projected to reach US$ 152.1 million by 2027; it is expected to grow at a CAGR of 9.7% from 2019 to 2027.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021.

Augmenta Bioworks, and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), today announced positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody (“mAb”) therapy, AUG-3387, binds to and neutralizes the SARS-CoV-2 Delta variant (B.1.617.2).

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 5, 2021 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2021.

Microbion Corporation of Bozeman, MT, announced that Mr. Robert A. Gillam, CFA, will be joining Microbion’s Board of Directors as Chairman, replacing Mr. Karim Lalji in the Board Chairman role effective immediately.